PATENT CLAIM ANALYSIS

Application Number: 16403176
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-08
Patent Classification: ["424", "489000"]

Abstract:
Embodiments are directed to a secnidazole formulations and the use of a secnidazole formulation for the treatment of bacterial vaginosis (BV).

Claim (Index 53):
A single dose pharmaceutical composition for treating bacterial vaginosis in a subject in need thereof comprising a therapeutically effective amount of secnidazole in a microgranule formulation, wherein the microgranule formulation comprises a plurality of microgranules having a particle size in the range of 400 micrometers to 841 micrometers, and wherein the therapeutically effective amount of secnidazole in the microgranule formulation is an amount of secnidazole that exhibits a maximum plasma concentration (Cmax) of about 34.5 \u03bcg/ml to about 58.3 \u03bcg/ml, or about 17.4 \u03bcg/ml to about 26.5 \u03bcg/ml in the subject, wherein the single dose pharmaceutical composition is for oral administration, and wherein secnidazole is the sole drug in the microgranule formulation.

Metadata:
- Claim Count in Document: 146.0
- Percentile: 100.0
- Lexical Diversity: 1.2
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14846505', '16049032', '13472953', '15990010', '13982675']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7524959505331366
- 35 USC 102 Novelty (BERT): 0.7360570461046296
- Combined Prediction Score: 0.7508520600902859
- Mean Citation Score: 462.23057400000016
- Max Citation Score: 835.29974
- Similarity Product: 744.6772827607157

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test